NZ207962A - Synergistic pharmaceutical compositions for treatment of seizure disorders - Google Patents

Synergistic pharmaceutical compositions for treatment of seizure disorders

Info

Publication number
NZ207962A
NZ207962A NZ207962A NZ20796284A NZ207962A NZ 207962 A NZ207962 A NZ 207962A NZ 207962 A NZ207962 A NZ 207962A NZ 20796284 A NZ20796284 A NZ 20796284A NZ 207962 A NZ207962 A NZ 207962A
Authority
NZ
New Zealand
Prior art keywords
seizures
glycine
gvg
sarcosine
gaba
Prior art date
Application number
NZ207962A
Other languages
English (en)
Inventor
N Seiler
S Sarhan
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NZ207962A publication Critical patent/NZ207962A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ207962A 1983-04-29 1984-04-26 Synergistic pharmaceutical compositions for treatment of seizure disorders NZ207962A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838311804A GB8311804D0 (en) 1983-04-29 1983-04-29 Treatment of seizure disorders and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NZ207962A true NZ207962A (en) 1986-12-05

Family

ID=10541938

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ207962A NZ207962A (en) 1983-04-29 1984-04-26 Synergistic pharmaceutical compositions for treatment of seizure disorders

Country Status (15)

Country Link
US (1) US4540582A (Direct)
EP (1) EP0124091B1 (Direct)
JP (1) JPS59206309A (Direct)
AT (1) ATE48759T1 (Direct)
AU (1) AU563291B2 (Direct)
CA (1) CA1228818A (Direct)
DE (1) DE3480764D1 (Direct)
DK (1) DK160805C (Direct)
GB (2) GB8311804D0 (Direct)
GR (1) GR81966B (Direct)
IE (1) IE57286B1 (Direct)
IL (1) IL71650A (Direct)
NZ (1) NZ207962A (Direct)
PT (1) PT78492B (Direct)
ZA (1) ZA843032B (Direct)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1192892A (en) * 1992-01-10 1993-08-03 Natalya Mikhailovna Burbenskaya Pharmaceutical preparation of antistress, stress-preventive and nootropic action
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6713497B1 (en) * 2003-03-17 2004-03-30 Brookhaven Science Associates, Llc Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
US20090017047A1 (en) * 2004-06-11 2009-01-15 Egon Tech Preparation for the Prevention and Treatment of Stress Conditions as Well as Functional and Organic Disorders of the Nervous System and Metabolic Disorders
RU2007130941A (ru) * 2005-01-14 2009-02-20 Н.В. Органон (Nl) Ингибиторы повторного поглощения глицина для лечения зависимости от наркотиков и алкоголя
US20160151316A1 (en) * 2012-01-27 2016-06-02 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1111433A (en) * 1965-08-25 1968-04-24 Zoja Lab Chim Farm A method to potentiate the activity of a group of sedative,hypnotic and narcotic compositions
US3960927A (en) * 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2437834A1 (fr) * 1978-10-04 1980-04-30 Lejeune Jerome Compositions pharmaceutiques a base de l-serine ou de glycine
GB2120244B (en) * 1982-05-17 1985-05-01 Merrell Toraude & Co Aminoalkadiene derivative

Also Published As

Publication number Publication date
US4540582A (en) 1985-09-10
PT78492A (en) 1984-05-01
IE841048L (en) 1984-10-29
DK213484A (da) 1984-10-30
DK213484D0 (da) 1984-04-27
AU2644384A (en) 1984-11-01
GB2138680A (en) 1984-10-31
ATE48759T1 (de) 1990-01-15
IL71650A0 (en) 1984-07-31
GB2138680B (en) 1986-05-21
EP0124091A3 (en) 1987-10-07
DK160805C (da) 1991-10-07
EP0124091A2 (en) 1984-11-07
EP0124091B1 (en) 1989-12-20
DK160805B (da) 1991-04-22
GB8311804D0 (en) 1983-06-02
JPS59206309A (ja) 1984-11-22
AU563291B2 (en) 1987-07-02
ZA843032B (en) 1984-11-28
IE57286B1 (en) 1992-07-15
DE3480764D1 (de) 1990-01-25
PT78492B (en) 1986-06-11
JPH0527606B2 (Direct) 1993-04-21
GB8410504D0 (en) 1984-05-31
CA1228818A (en) 1987-11-03
IL71650A (en) 1988-07-31
GR81966B (Direct) 1984-12-12

Similar Documents

Publication Publication Date Title
US6562865B1 (en) Composition comprising a tramadol material and an anticonvulsant drug
US5605911A (en) Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
ES2500053T3 (es) Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
AU765038B2 (en) Method for the treatment of insomnia
DE69904922T2 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
US5034400A (en) Method for preventing neurotoxic side effects of NMDA antagonists
US4540582A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
MX2012007778A (es) Diazoxido para su uso en el tratamiento o prevencion de una enfermedad desmielinizante autoinmunitaria del sistema nervioso central (snc).
US6326374B1 (en) Compositions comprising GABA analogs and caffeine
US4595697A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
US5616618A (en) Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
KR20130103342A (ko) 신경장애성 동통의 치료제 또는 예방제
EP1084704B1 (en) Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
JPH045231A (ja) 慢性痛用鎮痛剤
Seiler et al. Amplification by glycine of the anticonvulsant effect of THPO, a GABA uptake inhibitor
EP0637956B1 (en) Use of remacemide for the treatment of parkinson's disease
US20060199841A1 (en) Pharmaceutical combination for the treatment of spasticity and/or pain
RU2213561C2 (ru) Болеутоляющие композиции, содержащие ненаркотический анальгетик и усилитель анальгезии
KR20250164296A (ko) 우울증의 치료를 위한 5-메톡시-2-아미노인단을 포함하는 조성물
UA128174C2 (uk) Фармацевтична комбінація, що містить тразодон для лікування невропатичного болю
JP2000072668A (ja) 神経保護剤